Sun Pharma halts Assam eye drop production after regulatory order

Why production was suspended

The Central Drugs Standard Control Organisation (CDSCO) and Assam drug regulators ordered Sun Pharmaceutical Industries to halt production, sale, and distribution of ophthalmic products at its Assam facility on August 20. The order followed a joint inspection that uncovered deficiencies in the plant’s quality management system.

Regulators issued a show-cause notice to Sun Pharma on August 10, citing shortcomings in quality control. They were dissatisfied with the company’s response, leading to the suspension. Sun Pharma cannot resume production until regulators approve its compliance report outlining corrective measures.

Scope of the recall

In July, Sun Pharma voluntarily recalled 332 batches of ophthalmic products and 11 eye-care brands, including Lotepred 1% 5ml eye drops, Nepalact OD, Nepalact-Z, Brinzotim 5ml, and Depopred 2ml. These products were used to treat eye inflammation, infections, and chronic conditions.

Most of the recalled batches were manufactured at the company’s facility in Kokjhar village, Assam. Regulators have not confirmed whether the recalled products were contaminated, exported, or caused adverse effects in patients.

Revenue impact

Sun Pharma’s ophthalmology segment contributes approximately 3% to its domestic revenue. The company reported a decline in second-quarter profit, partly due to a one-time charge related to its acquisition of US-based Organon, though the recall’s direct financial impact remains unclear.

What this means

Lazyfounder analysis — our interpretation, not reported fact.

For pharmaceutical founders and operators, this regulatory action underscores the critical importance of robust quality management systems. Even a single plant’s deficiencies can trigger nationwide recalls, production halts, and reputational damage—regardless of the affected segment’s revenue contribution. The fact that regulators rejected Sun Pharma’s initial response suggests that compliance must go beyond paperwork; corrective measures must demonstrate tangible, verifiable improvements.

For investors, this development is a reminder that quality control failures can disrupt operations and revenue streams, even in non-core segments. The lack of clarity on contamination or adverse effects also highlights the potential for prolonged regulatory scrutiny, which could extend beyond the immediate recall.

Related on Lazyfounder

• More health news